ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1700

Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa

Matthew Got1, Suzanne Li2, Anthony V. Perruccio3,4, Dafna D Gladman1 and Vinod Chandran5, 1University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 4Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 5Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, measure and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Session Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: PASDAS is a composite disease activity measure (range 0–10) for psoriatic arthritis (PsA). Recently, PASDAS disease activity cutoffs were proposed and a minimal disease activity (MDA) state for PsA was also defined as a target for treatment. We aimed to establish a cutoff value of PASDAS that defines MDA state, to validate previously defined PASDAS cutoffs for low and high disease activity (3.2 and 5.4), and to define PASDAS cutoffs reflecting disease activity in our cohort.

Methods: All patients meeting CASPAR criteria were prospectively recruited from a PsA clinic and items necessary to complete the PASDAS and the MDA were evaluated. For aim 1, ROC curve analysis determined the optimal PASDAS cutoff discriminating patients based on MDA state. This analysis was subsequently repeated twice changing the discriminating criteria to meeting 6 of 7 and all 7 of the 7 MDA criteria. For aim 2 sensitivity and specificity of the previously defined PASDAS cutoffs for high and low disease activity were determined. For aim 3 patients were dichotomized based on the decision to escalate treatment by the treating physician (indicator of high disease activity). ROC curve analysis (90% specificity) estimated the PASDAS cutoff for high disease activity. Further, the median value of PASDAS for each treatment change group estimated PASDAS cutoffs for low and high disease. Lastly, ROC curves (90% specificity) estimated PASDAS cutoffs using patient’s global assessment of disease activity (PGA) as an external standard (<10 low; ≥10 moderate <60; ≥60 high). The mean values obtained by the 3 methods defined the final PASDAS cutoffs.

Results: 178 patients [53.9% male, mean age 56.8 years, disease duration 17.6 years, mean (SD) PASDAS 3.29 (1.29), 48.9% in MDA] were recruited. See table 1. PASDAS of <3.2 defined MDA (AUC- 0.96, sensitivity 88% [95% CI: 80-93%], specificity 92% [95% CI: 84-96%], Youden index- 0.80). For MDA based on meeting 6 of 7 criteria and all 7 of 7 criteria PASDAS scores of 2.6 and 2.1 maximized sensitivity and specificity, respectively. The published PASDAS cutoffs showed the following sensitivities and specificities (%), respectively: low- 100, 56; high- 12, 99 (PGA as external criterion). ROC curve analysis using treatment escalation as discriminating variable estimated a PASDAS high disease activity cutoff of 4.7 (AUC- 0.76). Median PASDAS of escalation and no-escalation groups were 4.17 and 2.86, respectively. When using PGA, PASDAS cutoffs for low and high disease were 2.08 (AUC- 0.95) and 4.14 (AUC- 0.93), respectively. The final PASDAS cutoffs (mean of 3 methods) for low and high disease activity cutoffs were 2.5 and 4.3, respectively.

Conclusion: A PASDAS score <3.2 reflects MDA. MDA based on stricter criteria may better reflect low disease activity state. Previously defined PASDAS cutoff for low disease activity state has high sensitivity while high disease activity cutoff has high specificity. Our cohort produced lower cutoffs.

Table 1: Cutoff values of PASDAS obtained from various methods.
Cutoff ROC curve (MDA 5/7) ROC curve (MDA 6/7) ROC curve (MDA 7/7) ROC curve (treatment escalation) Median Scores ROC curve (PGA) Final PASDAS (means)
MDA state

3.2

2.6

2.1

–

–

–

–

Low disease activity state

–

–

–

–

2.86

2.08

2.5

High disease activity state

–

–

–

4.7

4.17

4.14

4.3


Disclosure: M. Got, None; S. Li, None; A. V. Perruccio, None; D. D. Gladman, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2,AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 5; V. Chandran, None.

To cite this abstract in AMA style:

Got M, Li S, Perruccio AV, Gladman DD, Chandran V. Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/treating-psoriatic-arthritis-psa-to-target-defining-psoriatic-arthritis-disease-activity-score-pasdas-that-reflects-disease-activity-in-psa/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treating-psoriatic-arthritis-psa-to-target-defining-psoriatic-arthritis-disease-activity-score-pasdas-that-reflects-disease-activity-in-psa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences